"This is a great victory for our farmers, for citizens of India, as now the CCI has stopped the poison makers - Monsanto and Bayer from merging in India.
German drugs and pesticides maker Bayer forecast a year without earnings growth for its agricultural products business on Wednesday, as it seeks to complete its USD66 billion deal to take over U.S. seeds giant Monsanto.
Bayer now expects annual peak sales of more than 5 billion euros (USD 5.6 billion) for stroke prevention pill Xarelto, jointly sold with Johnson & Johnson, where it had previously seen about 3.5 billion.
The deal will create a company commanding more than a quarter of the combined world market for seeds and pesticides in the fast-consolidating farm supplies industry.
The breakthrough in negotiations, which follows more than four months of talks, came after Bayer further improved on the sweetened offer of USD 127.50 per share in cash it disclosed last week, the people said.
German pharmaceuticals and crop science major Bayer has yet again sweetened its offer to acquire US-based biotechnology firm Monsanto by over 2 per cent, taking the value to over USD 65 billion.
Executives from companies including the local businesses of Monsanto, Bayer, Dow, Dupont Pioneer and Syngenta announced the alliance in a crowded Press Club of India conference room.
The India businesses of Monsanto, Bayer, Dow, Dupont Pioneer and Syngenta have joined the group, which was about to hold a news conference.
Baumann also said any combination of Monsanto and Bayer's Crop Science unit would be "under our full control and ownership".
"Bayer executives recently met with executives of Monsanto to privately discuss a negotiated acquisition of Monsanto Company," the Leverkusen-based company said in a statement.
Pfizer sought a patent that covers an important chemical formulation of the active compound in the medicine, but the Indian Patent Office said the company would have to establish that the compound for which it is seeking a patent is therapeutically more effective than the active compound.
US trade representative Michael Froman in a meeting with Indian commerce minister Anand Sharma today raised concerns about Intellectual Property Rights (IPR) climate in India.
Novartis‘ and Bayer‘s patent battles in India reflect the increasing legal nature of the globalising pharma industry, Mylan Inc CEO Heather Bresch tells Forbes India.
Shares of Natco Pharma rallied as much as 11.7 percent in early trade on Tuesday as the company won Nexavar case against Bayer.
An Indian patent appeals board dismissed on Monday Bayer AG's petition against a government decision to allow a domestic company to sell cheap copycat versions of cancer drug Nexavar, delivering a blow to global drugmakers' monopolies on high-priced medicines.
Hotel Leela | SpiceJet | HOEC | Cholamandalam Investment | Nalco | Manaksia | Bayer | 3i Infotech and PC Jeweller are stocks, which are in the news today.
The third quarter advance corporate tax collection from the top 100 companies from the city has shown a modest 15 per cent growth year-on-year backed by higher payouts by the banking and financial sector, according to the income tax department sources.
German drugmaker Bayer has filed a lawsuit in the United States against Indian generic drug maker Lupin , to prevent it from selling a version of Bayer's birth-control pill Natazia in the US.
YK Hamied has public health on the top of his agenda. In his effort to make drugs affordable, he is not afraid to take on the biggies.
Chennai may be a long way from the Leverkusen headquarters of Bayer BAY, but the German pharmaceutical group is involved in a legal dispute in the southern Indian city that is being watched by its peers around the world.
German drugmaker Bayer may be fighting it out in the courtroom to defend its patent rights on cancer drug Nexavar. But out in the market, it's already lost considerable market share to cheaper variants from Cipla and Natco.
CNBC-TV18's Archana Shukla reports that India's grant of a compulsory licence to Natco for Bayer's kidney-cancer drug Nexavar has sent shockwaves across the globe
By granting compulsory license to Natco for Bayer's kidney cancer drug Nexavar, the Indian government has opened a legal can of worms, reports CNBC-TV18's Archana Shukla.
Global pharmaceutical giant Bayer has challenged the compulsory license granted by India‘s drug regulator to local generic firm Natco and the hearing begins on the August 21.
Nata Menabde, country head, WHO, tells Forbes India that governments should take measures to improve access to life-saving drugs, but be sensitive to pharmaceutical industry's concerns